BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28749576)

  • 1. Review of the current medical literature and assessment of current utilization patterns regarding mismatch repair protein immunohistochemistry in cutaneous Muir-Torre syndrome-associated neoplasms.
    Lee JB; Litzner BR; Vidal CI
    J Cutan Pathol; 2017 Nov; 44(11):931-937. PubMed ID: 28749576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal immunohistochemical screening of sebaceous neoplasms for Muir-Torre syndrome: Putting the cart before the horse?
    Kim RH; Nagler AR; Meehan SA
    J Am Acad Dermatol; 2016 Nov; 75(5):1078-1079. PubMed ID: 27745640
    [No Abstract]   [Full Text] [Related]  

  • 3. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
    Jessup CJ; Redston M; Tilton E; Reimann JD
    Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
    Ponti G; Manfredini M; Tomasi A; Pellacani G
    Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Muir-Torre syndrome and Turcot syndrome].
    Velter C; Caussade P; Fricker JP; Cribier B
    Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.
    Cohen PR; Kurzrock R
    Cureus; 2023 Jan; 15(1):e33975. PubMed ID: 36824550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations on the performance of immunohistochemistry for mismatch repair gene proteins in cases of sebaceous neoplasms and keratoacanthomas with reference to Muir-Torre syndrome.
    Fernandez-Flores A
    Am J Dermatopathol; 2012 Jun; 34(4):416-22. PubMed ID: 22123265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases.
    Boennelycke M; Thomsen BM; Holck S
    Pathol Res Pract; 2015 Jan; 211(1):78-82. PubMed ID: 25457183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.
    Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q
    Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Muir-Torre syndrome associated with Waldenstrom's macroglobulinemia].
    Velter C; Bourlond F; Wettle C; Lioure B; Lipsker D; Maugard C; Cribier B
    Ann Dermatol Venereol; 2016 Dec; 143(12):825-830. PubMed ID: 27771121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
    Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
    Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
    Abbas O; Mahalingam M
    J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome.
    Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML
    Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Muir-Torre syndrome: rare association with duodenal carcinoma].
    Bacha D; Deschamps L; Sauvanet A; Couvelard A
    Ann Pathol; 2009 Dec; 29(6):495-8. PubMed ID: 20005439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MSH6 mutation in a family affected by Muir-Torre syndrome.
    Kacerovska D; Cerna K; Martinek P; Grossmann P; Michal M; Ricar J; Kazakov DV
    Am J Dermatopathol; 2012 Aug; 34(6):648-52. PubMed ID: 22814321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
    Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
    J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
    Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
    J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of Muir-Torre syndrome with a keratoacanthoma and sebaceous neoplasms: Clinicopathological features and a speculation on the pathogenesis of cutaneous tumor type.
    Takayama E; Yoshioka A; Takai T; Goto K
    J Dermatol; 2021 May; 48(5):690-694. PubMed ID: 33523490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biallelic MYH germline mutations as cause of Muir-Torre syndrome.
    Guillén-Ponce C; Castillejo A; Barberá VM; Pascual-Ramírez JC; Andrada E; Castillejo MI; Guarinós C; Molina-Garrido MJ; Carrato A; Soto JL
    Fam Cancer; 2010 Jun; 9(2):151-4. PubMed ID: 19998059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
    Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
    JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.